ArticlePDF Available

Childhood neuro-motor disorders treated with silica-rich mineral water: A case report

Authors:
  • Univ. of Maryland
Case Report http://doi.org/10.18231/j.jpmhh.2019.013
Journal of Preventive Medicine and Holistic Health, January-June, 2019;5(1):70-72 70
Childhood neuro-motor disorders treated with silica-rich mineral water: A case report
Tullio Grassi
Faculty Specialist, Dept. of Physics, University of Maryland, USA
*Corresponding Author: Tullio Grassi
Email: tgrassi@umd.edu
Abstract
Previous works have shown the benefits of drinking silica-rich mineral water by patients diagnosed with specific neurological
diseases. The suggested mechanism is that silica-rich water facilitates the removal of aluminum from the body and the
nervous system. This report describes the case of a child with a mix of neurological and motor symptoms that have greatly
decreased while drinking silica-rich water over a period of less than one year. These improvements also show a correlation
with EEG results. A discussion of potential sources of aluminum that the child was exposed to is also included.
Keywords: Child, Neurological disorders, Motor skills, Seizures, Silicon, Aluminum.
Case Report
A previously healthy male child, between three or four years
of age, started to present the following symptoms: shaking
repeatedly his head left and right as if to say "no", pain in
the legs without apparent reason, chronic cough during
sleeping time without symptoms of either a cold or a
gastroesophageal reflux disease. These symptoms were not
of sufficient concern to be reported to doctors.
When the child reached 52months of age, new, more
serious symptoms appeared including episodes of full-body
involuntary movements and absence seizures that included
not responding to words and appearing confused or in a
haze. Each of these episodes typically had a duration of less
than a minute. The child was taken to the emergency room
of a children’s university hospital in Switzerland. The
family had taken video recordings of the movements and
these were shown to doctors.
Full-body involuntary movements were of two types:
one type was walking in a repetitive pattern, while making
anomalous movements of hands, arms, feet. The other type
happened when the child was either in bed or on a similarly
flat surface. In this type, the movement was starting from a
knee-elbow position, then the child suddenly pushed his
legs making a small horizontal jump and often hitting his
head on obstacles in front of him.
There is no family history of neurological disorders. The
child’s two parents and four grandparents have never been
diagnosed with neurological disorders.
After the appearance of more serious symptoms, these
symptoms were more carefully observed and recorded in a
journal. The following three additional anomalies were
noted:
1. During sleep the child had shaking and tremors of body
parts, the tremors were not visible by eye but was very
clear by touching the child, and these tremors typically
happened in bursts;
2. While awake, for a period of less than a minute, the
child did not respond to words and did not remember
appealing words told to him (the word “chocolate” was
normally used);
3. While awake, for a period of less than a minute, strange
smiling expressions with no apparent reason.
The last two symptoms observed when the child was awake
seem similar to absence seizures.
During a 24-hour period the child had an average of about
seven involuntary full-body episodes, and a higher amount
of episodes with the other anomalies. In the subsequent
months the child was able to explain that during these
episodes, his arms or legs were moving by themselves and
he did not like that; on the contrary he liked the left-right
head shaking. When he had a strange smiling expression, he
denied he was smiling. During the period with maximum
symptoms (age 52 and 53 months) the child showed
increased tiredness and problems of loss of balance when
walking, running, playing, in moments when apparently he
was not having the episodes previously described. The
episodes were rare when the child was focused on a task he
liked.
A 40-minute video-EEG was done 3 days after the visit
at the emergency room and revealed epileptiform patterns
(spike waves in the left back area of the brain). Initial report
from the neurology department described them as focal
epilepsy. Five days later, an 18-hour video-EEG was done.
Reports from these two EEGs agreed. However, later
analysis of the video recordings done during the EEGs
showed that the spike waves events did not correspond to
any anomalous body movement. At this point the hypothesis
of focal epilepsy was discarded.
Magnetic resonance imaging (MRI) did not show any
anomaly. Blood, urine, throat swab direct tests and cultures
were performed in order to investigate a hypothesis of
PANDAS. The tests did not reveal any sign of infection
(including Streptococcus Groups A, C, G), and did not show
anomalies with Anti-NMDA-Receptors.
Child neurologists from three different hospitals have
seen the child and the test results. They all agreed that the
child had one or more neurological disorders, and they
considered various diseases including epilepsy, PANDAS,
Tullio Grassi Childhood neuro-motor disorders treated with silica-rich mineral water: A…
Journal of Preventive Medicine and Holistic Health, January-June, 2019;5(1):70-72 71
complex tics, stereotyped movements, but they did not
confirm any of these diagnoses.
A change in the diet was introduced, replacing as much
as possible tap water with silica-rich mineral water, based
on positive results with this type of mineral water on various
neurological diseases.1,2 The mineral waters used for this
case were first the commercially available brand Carrefour
Eau d'Auvergne, that is no longer available, and second
Volvic, both with a content of 32 mg/l of silica (SiO2).
Family members administered the silicon-rich water as
much as possible, however when the child was at pre-school
or school (about 9 hours per day, on normal school days) he
continued drinking tap water. The child has maintained this
pattern of water intake to date. When the child started
drinking silica-rich mineral water he had also stopped
drinking infant formulas and started to have a more varied
diet. After two months of these changes in diet, the child’s
symptoms started to diminish. After eight months of this
new diet, the involuntary full-body movements were
reduced from the initial value of about 50 per week to about
5 per week (Fig. 1). A similar reduction was observed for
the other symptoms, including the chronic cough and
absence seizure frequency.
Fig. 1: Evolution over time of aluminum excretions and
episodes of full-body involuntary movements. EEG at 52
months of age showed epileptiform anomalies. Drinking of
silica-rich water started at 52.5 months. EEG at 64 months
showed normal results (no anomalies).
Several urine analyses were performed in order to measure
the amount of aluminum excreted. The results are plotted in
figure. The plot shows that the aluminum content of the
urine has decreased to a level below the detection capability
of the laboratory. This trend follows the decrease in the
neuro-disorders of the child. Another EEG was performed at
the age of 64 months and it was normal (no anomalies). The
child has never used any neurological drug, and he has not
used any drug on a regular basis.
Discussion
For this case, it has not been possible to formulate a clear
diagnosis based on documented diseases, and this has
motivated further investigations. Medical literature 4,5 and
clinical experience show that it is not rare to have
neurological disorders appearing in children around 5 year
of age, and gradually declining during adolescence. In this
case, the symptoms were greatly reduced within less than a
year. This relatively fast evolution suggests that aluminum
accumulation causes neuro-disorders and drinking silicon-
rich water can cure these disorders.
Aluminum has no useful role in human beings and
animals and is a known neuro toxic element.3 This case
report shows that aluminum was present in the body, and
implies that silicon-rich water facilitated the removal of
some of it. During this removal process, the child’s neuro-
disorders, chronic cough and EEG results improved.
Another implication is that the chronic cough of this case
seems to be of neurological origin,6 as the other common
causes (cold, gastroesophageal reflux disease) did not match
the symptoms.
Potential sources of aluminum that the child was
exposed to were examined. Sources of aluminum reported in
literature are: tap water,7 infant formulas,8 other processed
foods,9 vaccines.3,10 Of these potential sources, tap water
from the house where the child has lived was tested and
showed a content of aluminum of 6.8 μg/l, which is well
within regulations and this content excludes tap water from
the significant sources of aluminum. The only processed
food that he had on a regular basis were infant formulas
(Aptimal brand). Mitkus et al.11 estimated the body burden
of aluminum during the first 400 days of life for infants on
formula diets and for a standard vaccination schedule, and
the estimates show that the burden of aluminum from
vaccinations exceeds that from dietary sources.11 The
child’s aluminum containing vaccinations were: Infanrix
DTPa-IPV+Hib (4 doses at 500 μg aluminum per dose),
Prevenar13 (3 doses at 125 μg aluminum per dose),
NeisVac-C Baxter (1 dose at 500 μg aluminum per dose).
The child was also vaccinated with Priorix (2 doses) but this
vaccine does not contain an aluminum adjuvant.
Aptimal First Milk powdered infant formulas have been
tested for aluminum and found to result in the ingestion of
124 μg of aluminum per day on average.8 Aptimal Follow
On powdered infant formulas were also tested and found to
result in the ingestion of 137 μg of aluminum per day on
average.8 Unlike vaccinations that are 100% bioavailable,
only 0.2% (0.25 to 0.27 μg) of the aluminum per day is
estimated on average to be absorbed by the gut from these
Aptimal formulas and made bioavailable to a child’s body.12
After four years on these infant formulas the child
absorbed approximately 390 μg of aluminum, while the total
amount of aluminum added to the child’s body by
vaccinations is estimated to be 2875 μg.
Tullio Grassi Childhood neuro-motor disorders treated with silica-rich mineral water: A…
Journal of Preventive Medicine and Holistic Health, January-June, 2019;5(1):70-72 72
Conclusions
The presented case suggests that aluminum can be a cause
of child intoxication. Moreover, it shows that silica-rich
mineral water can be used as a treatment for these cases.
Source of Funding: None.
Conflicts of Interest: None.
References
1. Exley C, Mamutse G, Korchazhkina O, Pye E, Strekopytov S,
Polwart A, et al. Elevated urinary excretion of aluminium and
iron in multiple sclerosis. Mult Scler 2006;12(5):53340.
2. Davenward S, Bentham P, Wright J, Crome P, Job D, Polwart
A, et al. Silicon-rich mineral water as a non-invasive test of the
“aluminum hypothesis” in Alzheimer’s disease. J Alzheimers
Dis 2013;33(2):42330.
3. Shaw CA, Tomljenovic L. Aluminum in the central nervous
system (CNS): toxicity in humans and animals, vaccine
adjuvants, and autoimmunity. Immunol Res 2013;56(23):304
16.
4. Gillberg IC, Gillberg C, Groth J. Children with preschool
minor neurodevelopmental disorders. V: Neurodevelopmental
profiles at age 13. Dev Med Child Neurol 1989;31(1):1424.
5. Groth C. Tourette syndrome in a longitudinal perspective.
Clinical course of tics and comorbidities, coexisting
psychopathologies, phenotypes and predictors. Dan Med J
2018;65(4).
6. Niimi A, Chung KF. Evidence for neuropathic processes in
chronic cough. Pulm Pharmacol Ther 2015;35:1004.
7. Rondeau V, Commenges D, Jacqmin-Gadda H, Dartigues J-F.
Relation between Aluminum Concentrations in Drinking
Water and Alzheimer’s Disease: An 8-year Follow-up Study.
Am J Epidemiol 2000;152(1):5966.
8. Chuchu N, Patel B, Sebastian B, Exley C. The aluminium
content of infant formulas remains too high. BMC Pediatr
2013;13:162.
9. Sato K, Suzuki I, Kubota H, Furusho N, Inoue T, Yasukouchi
Y, et al. Estimation of daily aluminum intake in Japan based on
food consumption inspection results: impact of food additives.
Food Sci Nutr 2014;2(4):38997.
10. Shardlow E, Mold M, Exley C. Unraveling the enigma:
elucidating the relationship between the physicochemical
properties of aluminium-based adjuvants and their
immunological mechanisms of action. Allergy Asthma Clin
Immunol 2018;14:80.
11. Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO.
Updated aluminum pharmacokinetics following infant
exposures through diet and vaccination. Vaccine 2011 Nov
28;29(51):953843.
12. Yokel RA, McNamara PJ. Aluminium toxicokinetics: an
updated minireview. Pharmacol Toxicol 2001;88(4):15967.
How to cite this article: Grassi T. Childhood neuro-motor
disorders treated with silica-rich mineral water: A case report.
J Prev Med Holistic Health 2019;5(1):70-72.
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Abstract Aluminium salts are by far the most commonly used adjuvants in vaccines. There are only two aluminium salts which are used in clinically-approved vaccines, Alhydrogel® and AdjuPhos®, while the novel aluminium adjuvant used in Gardasil® is a sulphated version of the latter. We have investigated the physicochemical properties of these two aluminium adjuvants and specifically in milieus approximating to both vaccine vehicles and the composition of injection sites. Additionally we have used a monocytic cell line to establish the relationship between their physicochemical properties and their internalisation and cytotoxicity. We emphasise that aluminium adjuvants used in clinically approved vaccines are chemically and biologically dissimilar with concomitantly potentially distinct roles in vaccine-related adverse events.
Article
Full-text available
Dietary aluminum (Al) intake by young children, children, youths, and adults in Japan was estimated using the market basket method. The Al content of food category (I–VII) samples for each age group was determined by inductively coupled plasma-atomic emission spectrometry (ICP-AES). The Al content in processed foods and unprocessed foods ranged from 0.40 to 21.7 mg/kg and from 0.32 to 0.54 mg/kg, respectively. For processed foods in all age groups, the Al content in food category VI samples, sugar and confections/savories, was the highest, followed by those in category II, cereals. The daily dietary Al intake from processed foods was much larger than that from unprocessed foods. The mean weekly percentages of the provisional tolerable weekly intake (PTWI, established by the joint FAO/WHO Expert Committee on Food Additives in 2011) from processed foods for all age groups are 43.1, 22.4, 17.6 and 15.1%, respectively. Only the highest consumer Al exposure value (>P95) of the young children group exceeded the PTWI.
Article
Full-text available
Recent research published in this journal highlighted the issue of the high content of aluminium in infant formulas. The expectation was that the findings would serve as a catalyst for manufacturers to address a significant problem of these, often necessary, components of infant nutrition. It is critically important that parents and other users have confidence in the safety of infant formulas and that they have reliable information to use in choosing a product with a lower content of aluminium. Herein, we have significantly extended the scope of the previous research and the aluminium content of 30 of the most widely available and often used infant formulas has been measured. Both ready-to-drink milks and milk powders were subjected to microwave digestion in the presence of 15.8 M HNO3 and 30% w/v H2O2 and the aluminium content of the digests was measured by TH GFAAS. Both ready-to-drink milks and milk powders were contaminated with aluminium. The concentration of aluminium across all milk products ranged from ca 100 to 430 mug/L. The concentration of aluminium in two soya-based milk products was 656 and 756 mug/L. The intake of aluminium from non-soya-based infant formulas varied from ca 100 to 300 mug per day. For soya-based milks it could be as high as 700 mug per day. All 30 infant formulas were contaminated with aluminium. There was no clear evidence that subsequent to the problem of aluminium being highlighted in a previous publication in this journal that contamination had been addressed and reduced. It is the opinion of the authors that regulatory and other non-voluntary methods are now required to reduce the aluminium content of infant formulas and thereby protect infants from chronic exposure to dietary aluminium.
Article
Full-text available
We have examined the neurotoxicity of aluminum in humans and animals under various conditions, following different routes of administration, and provide an overview of the various associated disease states. The literature demonstrates clearly negative impacts of aluminum on the nervous system across the age span. In adults, aluminum exposure can lead to apparently age-related neurological deficits resembling Alzheimer's and has been linked to this disease and to the Guamanian variant, ALS-PDC. Similar outcomes have been found in animal models. In addition, injection of aluminum adjuvants in an attempt to model Gulf War syndrome and associated neurological deficits leads to an ALS phenotype in young male mice. In young children, a highly significant correlation exists between the number of pediatric aluminum-adjuvanted vaccines administered and the rate of autism spectrum disorders. Many of the features of aluminum-induced neurotoxicity may arise, in part, from autoimmune reactions, as part of the ASIA syndrome.
Article
Full-text available
There has been a plausible link between human exposure to aluminum and Alzheimer's disease for several decades. We contend that the only direct and ethically acceptable experimental test of the ‘aluminum hypothesis’, which would provide unequivocal data specific to the link, is to test the null hypothesis that a reduction in the body burden of aluminum to its lowest practical limit would have no influence upon the incidence, progression, or severity of Alzheimer's disease. Herein we are testing the hypothesis that silicon-rich mineral waters can be used as non-invasive methods to reduce the body burden of aluminum in individuals with Alzheimer's disease and a control group consisting of their carers and partners. We have shown that drinking up to 1 L of a silicon-rich mineral water each day for 12 weeks facilitated the removal of aluminum via the urine in both patient and control groups without any concomitant affect upon the urinary excretion of the essential metals, iron and copper. We have provided preliminary evidence that over 12 weeks of silicon-rich mineral water therapy the body burden of aluminum fell in individuals with Alzheimer's disease and, concomitantly, cognitive performance showed clinically relevant improvements in at least 3 out of 15 individuals. This is a first step in a much needed rigorous test of the ‘aluminum hypothesis of Alzheimer's disease’ and a longer term study involving many more individuals is now warranted.
Article
Full-text available
This MiniReview updates and expands the MiniReview of aluminium toxicokinetics by Wilhelm et al. published by this journal in 1990. The use of 26Al, analyzed by accelerator mass spectrometry, now enables determination of Al toxicokinetics under physiological conditions. There is concern about aluminium in drinking water. The common sources of aluminium for man are reviewed. Oral Al bioavailability from water appears to be about 0.3%. Food is the primary common source. Al bioavailability from food has not been adequately determined. Industrial and medicinal exposure, and perhaps antiperspirant use, can significantly increase absorbed aluminium. Inhalation bioavailability of airborne soluble Al appears to be about 1.5% in the industrial environment. Al may distribute to the brain from the nasal cavity, but the significance of this exposure route is unknown. Systemic Al bioavailability after single underarm antiperspirant application may be up to 0.012%. All intramuscularly injected Al, e.g. from vaccines, may eventually be absorbed. Al distributes unequally to all tissues. Distribution and renal excretion appear to be enhanced by citrate. Brain uptake of Al may be mediated by Al transferrin and Al citrate complexes. There appears to be carrier-mediated efflux of Al citrate from the brain. Elimination half-lives of years have been reported in man, probably reflecting release from bone. Al elimination is primarily renal with ≤2% excreted in bile. The contribution of food to absorbed Al needs to be determined to advance our understanding of the major components of Al toxicokinetics.
Article
Introduction: Tourette syndrome (TS) is a childhood onset neurodevelopmental disorder characterised by motor and vocal tics and frequent associated comorbidities. The developmental trajectory of tic shows tic-onset in the age of 4-6, peak in the age of 10-12 and decline during adolescence, although only few and small longitudinal studies form the basis of this evidence. Recent studies suggest that comorbid obsessive-compulsive disorder (OCD), attention deficit-hyperactivity disorder (ADHD) and coexisting psychopathologies tend to persist and become more dominant in adolescence. This large prospective follow-up study want to examine the clinical course of TS: tic and comorbidities during adolescence, the prevalence of coexisting psychopathologies, the tic-related impairment, development in phenotype expression and find predictors for the expected course of TS. Method: This study is examining a large clinical cohort recruited at the Danish National Tourette Clinic during the period 2005-2007 and 2011-2013. At baseline, 314 participants aged 5-19 years were included and at follow-up 6 years later 227 participated, aged 11-26. All participants were uniformly clinically examined at basis and follow-up with a clinical interview and validated measurements to assess comorbidities. The Yale Global Tic Severity Scale was used to asses tic severity and tic-related impairment. At follow-up a cross-sectional diagnostic evaluation was made with the Development and Well-Being Assessment to assess coexisting psychopathologies. Results: A significant decline in tic and the most frequent comorbidities OCD and ADHD was found although some variation existed and some subclinical and partial remissions persisted. Tic-related impairment was not reflected in the tic-decline as expected but influenced by several parameters. The phenotype expression was found to be dynamic but overall changed toward TS without comorbidities. Several predictors were found to predict the clinical course of TS in adolescence and early adulthood. Childhood tics, OCD and ADHD severity were the strongest predictors for future symptoms of the respectively diagnoses. Comorbidities and coexisting psychopathologies were found in 63% at follow-up, whereas 37% had pure TS. Conclusion: The clinical course of TS during adolescence was confirmed, with solid evidence, with decline in tics, OCD and ADHD severity. We provide evidence of considerable coexisting psychopathologies requiring clinical support and partial remissions and subthreshold symptoms requiring monitoring and clinical guidance to assist the young adults in promoting a healthy transition into early adulthood. Furthermore we provide predictors for the clinical course of TS to be used in the preventive efforts, early intervention and allocation of resources improving quality of life for the children and their families.
Article
Chronic cough is a very common symptom for which patients seek medical attention but can often be difficult to manage, because associated causes may remain elusive and treatment of any associated causes does not always provide adequate relief. Current antitussives have limited efficacy and undesirable side-effects. Patients with chronic cough typically describe sensory symptoms suggestive of upper airway and laryngeal neural dysfunction. They often report cough triggered by low-level physical and chemical stimuli supporting the recently emerging concept of 'cough hypersensitivity syndrome'. Chronic cough is a neuropathic condition that could be secondary to sensory nerve damage caused by inflammatory, infective and allergic factors. Mechanisms underlying peripheral and central augmentation of the afferent cough pathways have been identified. Successful treatment of chronic cough with agents used for treating neuropathic pain, such as gabapentin and amitriptyline, would also support this concept. Further research of neuropathic cough may lead to the discovery of more effective antitussives in the future.
Article
Aluminum is a ubiquitous element that is released naturally into the environment via volcanic activity and the breakdown of rocks on the earth's surface. Exposure of the general population to aluminum occurs primarily through the consumption of food, antacids, and buffered analgesics. Exposure to aluminum in the general population can also occur through vaccination, since vaccines often contain aluminum salts (frequently aluminum hydroxide or aluminum phosphate) as adjuvants. Because concerns have been expressed by the public that aluminum in vaccines may pose a risk to infants, we developed an up-to-date analysis of the safety of aluminum adjuvants. Keith et al. [1] previously analyzed the pharmacokinetics of aluminum for infant dietary and vaccine exposures and compared the resulting body burdens to those based on the minimal risk levels (MRLs) established by the Agency for Toxic Substances and Disease Registry. We updated the analysis of Keith et al. [1] with a current pediatric vaccination schedule [2]; baseline aluminum levels at birth; an aluminum retention function that reflects changing glomerular filtration rates in infants; an adjustment for the kinetics of aluminum efflux at the site of injection; contemporaneous MRLs; and the most recent infant body weight data for children 0-60 months of age [3]. Using these updated parameters we found that the body burden of aluminum from vaccines and diet throughout an infant's first year of life is significantly less than the corresponding safe body burden of aluminum modeled using the regulatory MRL. We conclude that episodic exposures to vaccines that contain aluminum adjuvant continue to be extremely low risk to infants and that the benefits of using vaccines containing aluminum adjuvant outweigh any theoretical concerns.
Article
A cohort of children diagnosed at age seven as suffering from deficits in attention, motor control and perception was compared at age 13 with a group of children without such problems. More than two-thirds of the index children no longer had any clearly detectable motor problems at 13, but they still had significantly prolonged complex reaction times. These results suggest that children with these deficits in the early school years have a fair biological prognosis by the early teen years. Enfants ayant présenté des troubles neurodéveloppementaux mineurs avant l'entrée à l'école. V: Profil neurodéveloppemental à 13 ans Une cohorte d'enfants chez qui un diagnostic de déficits d'attention, de contrôle moteur et de perception avait été porté à lâge de sept ans, ont été comparés à l'âge de 13 ans à un groupe d'enfants indemnes selon ces critères. Chez plus des deux tiers des enfants du groupe index, il n'y avait plus de difficultés motrices détectées à 13 ans mais le temps de réaction aux tâches complexes demeurait significativement prolongé. Ces résultats suggèrent un pronostic biologique médiocre à 13 ans chez les enfants présentant de tels déficits dans les premières années d'école. Kinder mit leichten entwicklungsneurologischen Störungen im Vorschulalter. V: Entwicklungsneurologisches Profil im Alter von 13 Jahren Eine Gruppe von Kindern, bei denen mit sieben Jahren Störungen in den Bereichen Aufmerksamkeit, Motorkontrolle und Perzeption festgestellt worden waren, wurden im Alter von 13 Jahren mit einer Gruppe von Kindern ohne solche Probleme verglichen. Bei mehr als zwei Drittel der Index Kinder fanden sich mit 13 Jahren keine klar erkennbaren motorischen Probleme mehr, aber sie hatten noch signifikant verlängerte Reaktionszeiten. Diese Ergebnisse lassen erkennen, daβ Kinder, die in den ersten Schuljahren diese Störungen haben, im fruhen Teenalter eine gute biologische Prognose haben. Prescolares con alteraciones menores en el comportamiento. V: Perfil neuroevolutivo a la edad de 13 años Un grupo de niños diagnosticados a la edad de siete años como pacientes de déficit de la atención, del control motor y de la percepción se comparó a la edad de 13 años con un grupo de niños sin estos problemas. Más de los dos tercios de los niños estudiados a los 13 años, ya no presentaban ningun problema motor claramente detectable, pero tenian aun unos tiempos de reacción complejos significativamente prolongados. Estos resultados sugieren que los niños con estos problemas en los primeros años escolares, tienen un pronóstico biológico bueno a la edad de diez años.